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Abstract
Background: The isolation of human monoclonal antibodies (mAbs) that neutralize a broad spectrum of primary HIV-1
isolates and the characterization of the human neutralizing antibody B cell response to HIV-1 infection are important goals
that are central to the design of an effective antibody-based vaccine.
Methods and Findings: We immortalized IgG
+ memory B cells from individuals infected with diverse clades of HIV-1 and
selected on the basis of plasma neutralization profiles that were cross-clade and relatively potent. Culture supernatants
were screened using various recombinant forms of the envelope glycoproteins (Env) in multiple parallel assays. We isolated
58 mAbs that were mapped to different Env surfaces, most of which showed neutralizing activity. One mAb in particular
(HJ16) specific for a novel epitope proximal to the CD4 binding site on gp120 selectively neutralized a multi-clade panel of
Tier-2 HIV-1 pseudoviruses, and demonstrated reactivity that was comparable in breadth, but distinct in neutralization
specificity, to that of the other CD4 binding site-specific neutralizing mAb b12. A second mAb (HGN194) bound a conserved
epitope in the V3 crown and neutralized all Tier-1 and a proportion of Tier-2 pseudoviruses tested, irrespective of clade. A
third mAb (HK20) with broad neutralizing activity, particularly as a Fab fragment, recognized a highly conserved epitope in
the HR-1 region of gp41, but showed striking assay-dependent selectivity in its activity.
Conclusions: This study reveals that by using appropriate screening methods, a large proportion of memory B cells can be
isolated that produce mAbs with HIV-1 neutralizing activity. Three of these mAbs show unusual breadth of neutralization
and therefore add to the current panel of HIV-1 neutralizing antibodies with potential for passive protection and template-
based vaccine design.
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Introduction
Neutralizing antibodies provide one arm of the adaptive
immune response against the human immunodeficiency virus
type 1 (HIV-1). Several reports demonstrated that the neutralizing
antibody response exerts selective pressure during HIV-1 replica-
tion in vivo, which accounts in part for the extensive variation in the
env gene observed soon after primary infection [1,2]. Furthermore,
selective pressure imposed by neutralizing antibodies has been
demonstrated in a human trial where three neutralizing
monoclonal antibodies (mAbs) administered during HAART
treatment-interruption led to a reduction in viremia followed by
selection of escape mutants [3,4]. Passive transfer studies in
macaques showed that the administration of HIV-1 neutralizing
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8805mAbs protects against vaginal or intravenous challenge with
SIV-HIV-1 chimeric viruses (SHIV) [5,6,7,8,9]. In some models
protection depended not only on viral neutralization but also on
Fc-mediated antibody effector functions [10,11].
Given the predicted low-titer inoculum driving HIV-1 sexual
transmission, a vaccine capable of eliciting antibodies that
neutralize a broad spectrum of viral strains could potentially
reduce or prevent infection. It has been anticipated that the
identification of broadly neutralizing mAbs from HIV-1 infected
individuals, and the characterization of their cognate epitopes will
be instrumental in the design of immunogens capable of eliciting
such a broad neutralizing response [12]. This idea has led to a
major international cooperative effort within consortia of labora-
tories with complementary expertise in human immunology,
structural biology and vaccine design [13,14].
HIV-1 is characterized by an extraordinary genetic diversity,
reflected by the presence of several clades (subtypes), a fact that
represents a significant impediment to vaccine development. Env is
the most variable HIV-1 gene, with up to 35% sequence diversity
among clades, 20% diversity within clades, and 10% diversity in a
single infected individual [15,16,17]. Several conserved epitopes
have been defined by a small panel of neutralizing mAbs isolated
using different experimental approaches. One epitope that appears
to be relatively conserved and overlaps with the CD4 binding site
(CD4bs) on the surface Env glycoprotein gp120 is recognized by
mAb b12, which is the most potent and broadly-reactive mAb of
such specificity [18,19,20]. This site was recently shown to be a
significant target of neutralizing antibodies present in the sera of
selected patients [21,22]. However, b12 was derived from a phage
library in which heavy and light chains have been randomly re-
assorted, thus its relevance to naturally-occurring B cell responses
in HIV-1 infection is unclear. A second epitope in a carbohydrate-
rich region on the outer domain of gp120 is composed of glycans
recognized by mAb 2G12, which shows an unusual interlocked
VH domain-swapped dimer generating an extended and mono-
valent binding surface [23,24,25,26]. The 2G12 epitope is not
present in the majority of clade C isolates [27], but, of more
concern, no 2G12-like activity has been detected in the sera of
HIV-1 infected individuals [21,22], suggesting that this type of
neutralizing antibody may not be generally amenable to elicitation
by B cells. A third target of the broadly-neutralizing mAb 4E10,
and relatively broad mAbs 2F5 and Z13, is located on the
membrane-proximal external region (MPER) of the transmem-
brane glycoprotein gp41 [28,29,30,31]. As with 2G12, MPER-
specific neutralizing antibodies are infrequently encountered in the
sera of HIV-1-infected individuals [21,32,33], potentially reducing
their relevance to vaccine development strategies. Moreover,
MPER-specific mAbs have features that suggest they are products
of autoreactive B cells, casting doubts over the possibility of
inducing such antibodies by vaccination [34]. A fourth target of
neutralizing mAbs is the V3 loop, which is immunogenic but also a
highly variable region involved in Env-coreceptor binding.
Antibodies to the V3 loop, such as mAbs 447-52D and F425-
B4E8, are mostly effective against neutralization sensitive (Tier-1)
viruses and have generally a limited breadth of reactivity almost
exclusively specific for clade B viruses, reflecting their provenance
from clade B-infected individuals [11,35,36,37]. A cluster of
human V3 mAbs raised from B cells derived from non-B clade-
infected individuals showed variable neutralizing activity for two
AG and two C clade primary isolates, although these were
particularly neutralization sensitive [38]. Finally, the CD4-induced
(CD4i) site has been described as a neutralization epitope
primarily on Tier-1 isolates with limited accessibility on Tier-2
isolates [39]. Very recently, the isolation and partial characteriza-
tion of two related MAbs from a clade A-infected donor that
appear to have very broad and potent neutralization profiles was
reported [40]. These MAbs recognize a discontinuous epitope only
expressed on the native Env trimer, made up of segments of the
CD4i, V2 and V3 loops. This publication is the first to provide
new broadly neutralizing reagents from a non-clade B donor and
provides proof-of-principle that new neutralization specificities
remain to be discovered on HIV-1 Env.
Since the number of existing neutralizing mAbs with a relatively
broad neutralization profile is very limited, and those described to
date, with the exception of the Walker et al MAbs were isolated
from clade B virus-infected donors, we undertook the task of
isolating new human mAbs from HIV-1-infected donors. Our
primary aims were: i) to isolate novel MAbs with cross-clade
neutralizing activity from non-B clade donors; ii) to analyze the
memory B cell repertoire in a representative panel of predomi-
nantly non-B clade-infected individuals. By using an improved
memory B cell immortalization method [41], combined with high-
throughput parallel screening with a panel of recombinant Env-
based antigens, we isolated a panel of 58 human mAbs which we
have characterized with regard to epitope specificity and breadth
of neutralization. We have more fully characterized three mAbs
from this panel that demonstrated complementary and relatively
broad cross-clade neutralizing profiles that target the gp120
CD4bs and the V3 crown, and the gp41 heptad repeat 1 (HR-1).
Materials and Methods
Ethics Statement
The study was approved by the ethical committee at Institute of
Tropical Medicine and Queen Mary University. All participants
gave written informed consent.
Cells and Reagents
TZM-bl and HOS.CD4-R5 cells were obtained from the NIH-
AIDS Research and Reference Reagent Program (ARRRP).
293T/17 cells were obtained from the ATCC. MAbs 2G12 [29],
2F5, 4E10 [42], b12 [18], 3D6 [43] and 5F3 [29] were obtained
from Polymun Scientific GmbH (Austria), as part of the
Collaboration for AIDS Vaccine Discovery program.
Viruses
The clade B and C HIV-1 Reference Panels of Env clones
[44,45] and the SF162 clone were obtained through the NIH-
ARRRP. Other non-clade B isolates were provided by the
Comprehensive Antibody Vaccine Immune Monitoring Consor-
tium (CA-VIMC). HIV-1 subtype B clone JRFL was provided by
Dennis Burton (Scripps Institute, La Jolla, US). Pseudoviruses
were produced by co-transfecting HEK293T/17 cells with the env-
expressing plasmids and the complementing viral-genome reporter
gene vector, pNL4-3.Luc
+.E
2R
+ (kindly provided by John R.
Mascola, VRC, NIAID, NIH, US).
Recombinant HIV-1 Envelope Glycoproteins
Recombinant gp140 from HIV-1 isolates 92UG37, CA18,
CN54, k530, UG21 and BR29 were provided by Simon Jeffs
(Imperial College London, UK). Recombinant gp120 from HIV-1
isolates CM235, 93TH975, BaL and SF162 were obtained
through the NIH-ARRRP, while gp160 from isolates MN and
LAI were purchased by Prospec-Tany Technogene LTD (Israel).
Recombinant YU2 gp120 and the two mutants D368R and I420R
were provided by John R. Mascola and Richard Wyatt (VRC,
NIAID, NIH, US). Recombinant soluble CD4 and recombinant
gp120 from HIV-1 IIIB and CN54 were obtained from the
HIV-1 Neutralizing Antibodies
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isolate HxB2 (amino acids 541-682) was purchased by Vybion Inc.
(US). HR-1 is a modified version of gp41 [46] exposing residues
HLLQLTVWGIKQLQARILAVE (HxB2). 5HB was produced as
described [47]. HR-1-FP comprises gp41-residues 512-594 (HxB2)
including the fusion peptide and HR-1. HR-2 (HxB2) comprises
gp41 residues 591–693 (HxB2) including the cys-loop region, HR-
2 and MPER flanked by two coiled coil regions.
Patient Selection and MAb Isolation
Patients were selected for inclusion into the study on the basis of
the clade of their infecting virus (predominantly non-B clade) and
on the ability of their plasma to neutralize a panel of HIV-1
primary isolates using two differerent assays. At the Institute
for Tropical Medicine a panel of 4 primary A strains (VI191,
92UG37, VI820, VI 1031), 4 primary C strains (VI829, VI882,
VI1144, VI1358) and 6 primary CRF02 strains (VI1090, VI2680,
CI20, CA18, VI1380, VI2727) was used to select patients with
.80% neutralization was measured at a 1/20 dilution of plasma.
The plasma dilution was mixed with virus for 24 hours and
absorbed to PHA/IL-2 stimulated freshly isolated PBMC for
1 hour. Virus-antibody mixture was then removed by extensive
washing and p24 ELISA was performed after 14 days of culture to
determine neutralization. At Queen Mary University of London,
the TZMbl-based recombinant pseudovirus assay was employed
with a selected panel of Tier 2-type clade A, B, C, CRF02_AG,
_AE, F and BF viruses to measure .50% neutralization at a 1/20
dilution. MAbs were isolated using a previously described
improved EBV immortalization method [41]. Culture superna-
tants were harvested 14 days after immortalization and assayed in
parallel for binding to trimeric gp140 proteins (UG37, clade A and
CN54, clade CRF07_BC) [48], monomeric gp120 (CN54,
CRF07_BC and IIIB, clade B) and gp41 recombinant ectodomain
(HxB2, clade B). Those that were positive were then subcloned
and grown up on a large scale for supernatant purification. The
purity of all mAb preparations was assessed using a chromogenic
LAL endotoxin assay (Genscript) and endotoxin levels were always
,0.05 EU/ml.
Binding Assays
A standard ELISA was used to determine binding of mAbs to
the panel of HIV-1 Envs. Briefly, ELISA plates were coated with
each Env antigen, blocked with 10% FCS in PBS, incubated with
human mAbs and washed. Bound mAbs were detected by
incubation with AP-conjugated goat anti-human IgG (Southern
Biotech). Plates were then washed, substrate (p-NPP, Sigma) was
added and plates were read at 405 nm. The relative affinities of
mAbs binding to respective coated antigens were determined with
ELISA by measuring the concentration of each mAb required to
achieve 50% maximal binding at saturation (K50). The ability of
mAbs to inhibit binding of sCD4 to gp120 or gp140 was evaluated
by ELISA. Serial dilutions of mAbs were pre-incubated with
gp120 (or gp140) and added to plates pre-coated with sCD4. After
1 h plates were washed and incubated with sheep polyclonal
antibody D7324 (Aalto Bio-Reagents) followed by washing,
incubation with AP-conjugated rabbit anti-sheep IgG antibody
(Abcam, Cambridge, UK), extensive washing and detection as
above.
Competition Assay
MAbs were purified on Protein G columns (GE Healthcare) and
biotinylated using the EZ-Link NHS-PEO solid phase biotinyla-
tion kit (Pierce). The competition between unlabeled and
biotinylated mAbs for binding to immobilized Env antigens was
measured by ELISA. Briefly, unlabelled competitor mAbs were
added at different concentrations. After 1 h biotinylated mAbs
were added at a concentration corresponding to the 70–80% of
the maximal OD level. After incubation for 1 h, plates were
washed and bound biotinylated mAb was detected using AP-
labeled streptavidin (Jackson Immunoresearch). The percentage of
inhibition was tested in triplicates and calculated as follow:
(12[(ODsample-ODneg ctr)/(ODpos ctr - ODneg ctr)])6100.
Peptide Scanning
Overlapping linear 15-mer and cyclized 15-mer peptides based
on gp160 of HIV-1 UG037 and 93MW965 and the overlapping
15-mer peptides of gp41 strain SF162 were synthesized on
polypropylene support (minicards), and were tested for reactivity
with mAbs as described [49,50]. Pepscan peptide binding analysis
was carried out by an ELISA-based format in which the colored
substrate was quantified with a charge-coupled device (CCD) -
camera and an image processing system. The values mostly ranged
from 0 to 3000, a log scale similar to 1 to 3 of a standard 96-well
plate ELISA-reader.
Neutralization Assays
A single-cycle infectivity assay was used to measure the
neutralization of luciferase-encoding virions pseudotyped with
the desired HIV-1 Env proteins, as previously described [51].
Briefly, appropriate dilutions of the virion-containing culture
supernatants were pre-incubated at 37uC for 1 h with mAbs at
various concentrations. The virus-mAb mixtures were added to
HOS-CD4-CCR5 cells and incubated for 3 days at 37uC. A
similar protocol was used for supernatants screening using TZM-bl
cells [45]. The cells were then lysed with Britelite reagent (Perkin-
Elmer) and the relative light units in the cell lysates were
determined on a luminometer microplate reader (Veritas, Turner
Biosystems). The 50% inhibitory dose (IC50) was defined as the
sample concentration at which relative luminescence units were
reduced 50% compared to virus control wells. Some of the
neutralization data for the reference mAbs b12, 2G12, 2F5 and
4E10 are taken from previous analyses [41,42] carried out under
identical standardized conditions to those used for the new mAbs
reported here. A multi-cycle virus replication assay was used to
measure the neutralization of replication competent luciferase-
encoding viruses in 5.25.EGFP.Luc.M7 cells [52]. This cell line is
a genetically engineered clone of CEMx174 that expresses
multiple SIV and HIV-1 entry receptors (CD4, CCR5, CXCR4,
GPR15/Bob) [53]. For the neutralization assay, 5000 tissue
culture infectious dose 50 (TCID50) of virus was incubated with
multiple dilutions of test sample in triplicate for 1 hr at 37uCi na
total volume of 150 ml in 96-well flat-bottom culture plates. A
100 ml suspension of cells (5610
5 cells/ml of growth medium
containing 25 mg DEAE dextran/ml) was added to each well.
Plates were incubated until approximately 10% of cells in virus
control wells were positive for GFP expression by fluorescence
microscopy (approximately 3 days). At this time, 100 ml of cell
suspension was transferred to a 96-well white solid plate (Costar)
for measurements of luminescence using the Britelite Lumines-
cence Reporter Gene Assay System (PerkinElmer Life Sciences).
Results
Isolation of HIV-1 Neutralizing mAbs from Memory B
Cells of Infected Donors
Plasma samples were obtained from patients entered into the
Antwerp and London cohorts who were infected with a variety of
HIV-1 clades. Patients were selected for MAb preparation on the
HIV-1 Neutralizing Antibodies
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clade), and on the ability of their plasma to neutralize, to .80% at
a 1/20 dilution, members of a selected panel of Tier 2-type clade
A, B, C, CRF02_AG, AE, F and BF viruses in both a PBMC-
based infectious primary isolate virus assay [54] and in the
TZMbl-based recombinant pseudovirus assay [55]. In some cases
only a restricted plasma neutralization analysis was possible due to
limiting amounts of patient plasma. Twelve and nine infected
donors from the London and Antwerp cohorts respectively were
selected for B cell immortalization. Summarized clinical and
virological data including HIV-1 clade, viremia, CD4
+ T cell
counts, therapy and breadth of neutralization are shown in
Table S1.
IgG
+ memory B cells were isolated from the selected donors and
immortalized with EBV in the presence of CpG as described [41].
The immortalization efficiency of memory B cells from HIV-1
patients was significantly lower than that of non-HIV-1-infected
donors (3% versus 20%, n=21, p,0.001). This finding may be
explained by the recent report that HIV-specific B cells are present
within a population of ‘‘exhausted’’ memory B cells, characterized
by the expression of inhibitory receptors and low levels of CD21
[56,57].To maximizedetectionofantibodiesrecognizingconserved
features, cell culture supernatants were screened by parallel high-
throughput ELISAs using five recombinant HIV-1 Env proteins,
including trimeric gp140 [48], monomeric gp120 and gp41
recombinant ectodomains. From the 21 donors interrogated we
selected 58 B cell clones producing mAbs that bound to at least one
of the screening antigens. The mAbs were purified and further
characterized for binding specificity and neutralizing activity using
an extended panel of recombinant Env proteins and pseudoviruses
representative of several HIV-1 clades with diverse coreceptor
usage, geographic origin and conformation.
The binding data for each mAb are displayed in Figure S1 and
expressed as half-maximal binding concentrations at equilibrium
(K50), which approximate to the equilibrium dissociation constants
[58]. Of the 58 mAbs, 37 bound to gp120 and 21 to gp41. Several
gp120-specific and gp41-specific mAbs showed a broad pattern of
reactivity with most recombinant proteins, although usually within
a broad range of K50 values. Overall, there was no relationship
between the donor’s HIV-1 clade and the clade specificity of the
isolated mAbs.
The neutralizing activity of the mAbs was initially measured
using 20 pseudotyped HIV-1 primary isolate envs characterized by
different sensitivity to neutralization [44,45]. The mAbs were
tested at a fixed concentration (100 mg/ml) in a luciferase-based
neutralization assay using HOS-CD4.R5 as target cells. Out of the
46 mAbs tested against the whole virus panel, 37 showed
neutralizing activity on at least one isolate (Figure 1A). Three
mAbs, HJ16, HGN194 and HK20, stood out for their breadth of
neutralizing activity, neutralizing 10, 11 and 17 out of the 20
pseudoviruses, respectively (Figure 1A). These mAbs were further
characterized in the same assay for their potency (Figure 1B).
HJ16 showed high neutralizing activity, while HGN194 and
HK20 were less potent. In addition, while most antibodies
preferentially neutralized Tier-1 isolates, HJ16 preferentially
neutralized Tier-2 isolates (Figure 1A-B).
Since it has been reported that HIV-1 neutralization is target
cell type-sensitive [59,60], we next used TZM-bl as target cells
and titrated the mAbs against a larger panel (n=46) of
predominantly (38/46) Tier-2 pseudoviruses (Table S2). Gener-
ally the results obtained with the extended panel confirmed the
previous results and showed that several mAbs had potent
neutralizing activity, with IC50 values ,20 ng/ml. A striking
exception was HK20, which neutralized 17/20 pseudoviruses in
the HOS-based assay, butonly 3/46pseudoviruses in the TZM-bl
based assay.
We established the breadth of neutralization of these three novel
mAbs by comparing them in the TZMbl assay with the five mAbs
currently considered to be the most broadly reactive, namely b12,
2G12, 2F5, 4E10 and 447-52D. We used a large multi-clade panel
comprising 10 Tier-1 and 82 Tier-2 isolates including clade B
early-transmitted viruses [61]. The three new mAbs showed a
pattern that was clearly distinct from that of previously described
mAbs (Figure 2). In particular, HGN194 neutralized with high
potency all Tier-1 viruses from clade A, B and C and 11% of Tier-
2 viruses. By contrast HJ16 neutralized only 1 out of 10 Tier-1
viruses, but neutralized 39% of Tier-2 viruses. Thus HJ16 is
comparable to b12 and 2F5 in terms of percentage of Tier-2
isolate neutralization and is superior to 2G12 and 447-52D. 4E10,
as previously reported [27,41] showed an extremely broad pattern
of reactivity. Taken together the above results indicate that novel
neutralizing mAbs can be isolated from memory B cells of non-
clade B HIV-1-infected individuals, some of which display
relatively broad neutralizing activity. Since one of our primary
aims was to isolate and characterize novel MAbs with unusually
broad and potent neutralization activity, we focused our attention
on HJ16, HK20 and HGN194.
HJ16, a Neutralizing mAb Binding a Novel Epitope
Proximal to the CD4bs
MAb HJ16, derived from a donor infected with clade C, has a
unique neutralization profile with potent and selective neutralization
of multiple Tier-2 pseudoviruses (Figure 1B and Figure 2). When
compared with the CD4bs-specific mAb b12 for gp120 binding,
HJ16 showed similar binding curves (Figure 3A) and inhibited to a
comparable extent the binding of gp120 to solid-phase sCD4
(Figure 3B,I C 50 values of 1.57 and 1.16 mg/ml, respectively).
However, cross-competition analysis of HJ16 and b12 for binding to
gp120 revealed incomplete heterologous inhibition, with plateau
values of approximately 80% (Figure 3C-D). These results suggest
that HJ16 and b12 recognize related but non-overlapping CD4bs-
proximal epitopes. To further characterize HJ16 specificity we
measured its binding to two YU2 gp120 mutants: the D368R
mutant, which is not bound by CD4 or CD4bs-specific mAbs [21]
and the I420R mutant, which is not recognized by CD4i-specific
mAbs [62]. As already reported, b12 bound the I420R CD4i
mutant, but failed to recognize the D368R CD4bs mutant. By
contrast, HJ16 bound both mutants and indeed bound better to
the D368R CD4bs mutant compared to the wild-type molecule
(Figure 3E-F). Attempts to map the epitope by Pepscan analysis
using overlapping linear peptides were unsuccessful (not shown),
consistent with HJ16 recognition of a discontinuous epitope.
HJ16 and b12 neutralized 1/10 and 8/10 Tier-1 and 32/82
and 35/82 Tier-2 pseudoviruses, respectively (Figure 2). Inter-
estingly, 22/32 Tier-2 isolates neutralized by HJ16 were not
neutralized by b12, and reciprocally 24/35 Tier-2 isolates
neutralized by b12 were not neutralized by HJ16. Another
interesting finding is that HJ16 does not discriminate between
clades as much as b12, 2G12 and 2F5 (e.g. b12 and 2G12 rarely
neutralize clade A isolates while 2F5 and 2G12 rarely neutralize
clade C isolates, Table S3). These results reveal a largely non-
overlapping pattern of reactivity of HJ16 and b12 and suggest that
the combination of these two mAbs could be effective against a
dominant fraction of HIV-1 isolates (57/82, i.e. 69%). Taken
together these results are consistent with HJ16 recognition of a
surface proximal to the CD4bs domain within gp120, but with an
epitope completely distinct from that recognized by b12.
HIV-1 Neutralizing Antibodies
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V3 Crown
MAb HGN194, isolated from a donor infected with
CRF02_AG clade, neutralized 11/20 pseudoviruses in the
HOS-based assay and 19/92 pseudoviruses in the TZM-bl-based
assay. Of note, HGN194 neutralized all Tier-1 isolates tested
(10/10 neutralized) across clades A, B, C and recombinant AG
and BC. Using Pepscan analysis with linear and cyclic peptide
libraries of gp120 the epitope recognized by HGN194 was
mapped to the sequence RRSVRIGPGQTF in the crown of the
V3-loop (Figure 4A). Similarly, the epitope of 7 additional gp120-
specific mAbs was mapped to the same V3 region using different
Figure 1. Neutralization of 20 HIV-1 isolates in HOS.CD4-R5 cells by a panel of human mAbs. (A) 46 mAbs (upper rows) were purified and
tested in triplicates at a fixed concentration (100 mg/ml; *50 mg/ml and **25 mg/ml) for their capacity to neutralize 20 HIV-1 pseudoviruses (left
columns) representing 6 different clades and both Tier-1 and Tier-2 isolates using HOS.CD4-R5 as target cells. Indicated is also the donor’s HIV-1 clade.
White, neutralization below 50%; yellow, 51–69%; orange, 70–89% and red, 90–100% neutralization. VSV-G pseudotyped HIV-1 was also tested as a
negative control. (B) HK20, HGN194 and HJ16 were tested in parallel with b12, 2G12, 2F5 and 4E10 for their capacity to neutralize 20 HIV-1
pseudoviruses representing 6 different clades and both Tier-1 and Tier-2 isolates using HOS-CD4.R5 cells as in (A). Shown are IC50 values in mg/ml.
-, indicates IC50 values .100 mg/ml.
doi:10.1371/journal.pone.0008805.g001
HIV-1 Neutralizing Antibodies
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8805Figure 2. Neutralization of 92 HIV-1 isolates in TZM-bl cells by HK20, HGN194, HJ16. HK20, HGN194 and HJ16 were tested in parallel with
b12, 2G12, 2F5, 4E10 and 447-52D for their capacity to neutralize 92 HIV-1 pseudoviruses representing 7 different clades and both Tier-1 and Tier-2
isolates using TZM-bl as target cells. Shown are IC50 values in mg/ml. -, indicates IC50 values .50 mg/ml, -* mAb tested starting from 25 mg/ml, nd,
not determined. MuLV pseudotyped HIV-1 was also tested as a negative control.
doi:10.1371/journal.pone.0008805.g002
HIV-1 Neutralizing Antibodies
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which each mAb was mostly reactive (Figure 4A). The minimal
sequence recognized by these mAbs ranged from 7 to 17 amino
acids and, with a single exception, comprised the G(A)PGR/Q/K
sequence, which is modeled to interact with CCR5 or CXCR4
during the viral entry process [63]. However, in contrast to
HGN194 which neutralizes with high potency all Tier-1 isolates
tested, the other V3-specific mAbs neutralized only a few Tier-1
isolates (Figure 1A-B and Figure 2), similar to the activity of
other recently characterized V3 loop-specific mAbs derived from
non-B clade infected individuals [38]. We confirmed the
neutralization activity of HGN194 in an M7 cell-based assay
challenged with replication-competent HIV-1 viruses carrying a
Luc reporter [52] and we observed that 3/5 clade B viruses were
neutralized (Table S5).
To better characterize the epitope recognized by HGN194 we
performed a replacement scanning of each position with the 18
complementary amino acids. This analysis revealed only 3 positions
(RRSVRIGPGQTF) where amino acid substitutions abrogated
binding. Remarkably, only one mutation out of the 21 found in viral
isolates (I to M in position 6) affected binding of HGN194
(Figure 4B–C). However, we observed that several HIV-1 isolates
that were not neutralized byHGN194 encoded the same amino acid
sequence shared by other HIV-1 isolates that were neutralized
(Figure 4B). For instance, the epitope RKSVRIGPGQTF
on 93MW965.26, which is strongly neutralized by HGN194 (i.e.
Figure 3. HJ16 binds to a CD4bs epitope distinct from that recognized by b12. (A) Binding of HJ16 and b12 to IIIB gp120 envelope protein.
(B) Inhibition of IIIB gp120 binding to immobilized sCD4 by HJ16 and b12. (C–D) Inhibition of binding of HJ16 (C) or b12 (D) to immobilized gp120 by
increasing concentrations of unlabeled HJ16 or b12. (E–F) Binding of b12 (E) or HJ16 (F) to YU2 wt gp120 and to the CD4i (I420R) or CD4bs (D368R)
mutant YU2 proteins. Shown is mean 6 SD of triplicates.
doi:10.1371/journal.pone.0008805.g003
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PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8805Figure 4. Epitope mapping of V3-specific mAbs by linear and circular peptide scanning. (A) Eight gp120-specific mAbs were mapped with
linear and cyclic peptides to the V3 region. Shown is the HIV-1 isolate used for the mapping, the minimal epitope, the binding breadth expressed as
number of recombinant Env proteins out of the 16 tested, and the fraction of isolates neutralized in the HOS and TZMbl-based neutralization assays,
respectively. (B) Alignment of the region corresponding to the epitope recognized by mAb HGN194 in 44 HIV-1 isolates. Co-receptor binding residues
are bold. Highlighted in grey are the isolates neutralized by HGN194 either in the TZMbl-based or in the HOS-based assays. (C) Replacement analysis
at positions R(307), S(308), V(309), R(310), I(311), G(312), Q(315), T(316 and F(317) of the epitope recognized by HGN194. Shown is the binding to 92
peptides carrying various amino acid substitutions at positions critical for maintenance of MAb binding. The bars represent ELISA values of HGN194
binding with the wt peptide (red) and the variant peptide (black). The amino acid replacements corresponding to V3 sequences from all isolates
shown in (B) are highlighted with green bars. The binding of antibody to each peptide was tested in a PEPSCAN-based ELISA. Numbering according
to HIV-1 HXB2.
doi:10.1371/journal.pone.0008805.g004
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Du172.17, isolates not neutralized by HGN194. This implies that
the HGN194 V3 epitope is unavailable for antibody recognition on
the assembled trimer of these non-neutralized isolates.
Taken together these results indicate that HGN194 has unusual
potency and breadth for a V3-specific monoclonal antibody. Of note,
HGN194 appears to have a broader reactivity than 447-52D since it
neutralizes all Tier-1 isolates and 11% of Tier-2 isolates, while 447-
52D neutralizes 88% of Tier-1 and 4% of Tier-2 isolates (Figure 2
and Table S3). Another V3 mAb with unusual breadth of activity is
F425-B4e8 [37]. We have not compared HGN194 with F425 here,
but F425-B4e8 appears somewhat broader than 447-52D, neutraliz-
ing 1 clade C and 2 clade D pseudoviruses [37]. Further comparison
between F425-B4e8 and HGN194 is difficult as different viruses and
assays were used to determine neutralization breadth and potency.
HK20, an HR-1 Specific mAb with Target Cell-Specific
Neutralizing Activity
HK20 was initially characterized as a gp41-specific mAb with
broad neutralizing activity in the HOS-based assay but lacking robust
activity in the TZM-bl assay. To map the epitope, we tested HK20
against all overlapping 15-mer peptides of the extracellular region of
HIV-1 gp41. HK20 bound peptide QQHLLQLTVWGIKQL that
overlaps the hydrophobic pocket sequence of HR-1 (Figure 5A).
The specificity of HK20 was confirmed by immunoprecipitation of
the 5-helix bundle (5HB) construct [47] and of a trimeric HR-1
construct that includes the gp41 fusion peptide, indicating that the
fusion peptide does not interfere with HK20 binding (Figure 5B). In
ELISA, HK20 bound to 5HB and HR-1 gp41 constructs with K50
values of 210 and 95 ng/ml, respectively and also to the gp41
ectodomain,althoughwithloweravidity(1.27 mg/ml)(Figure 5C),a
Figure 5. HK20 binds to the HR-1 region within gp41. (A) HK20 binding at 4 ug/ml to all overlapping linear peptides (15-mer peptides
overlapping by 14 residues) spanning the gp41 sequence of the HXB2 isolate. Numbers at X-axis denote the first amino-terminal residue of the 15-
mer gp41 peptide (numbering according to HIV-1 HXB2 sequence). Y- axis similar to Figure 4C (B) Immunoprecipitation of HR-1, 5HB and HR-1-FP
constructs in the presence (+) or absence (2) of HK20 mAb. Proteins were separated in 10% polyacrylamide gels under reducing conditions and
stained with Coomassie blue. C, HK20 mAb alone; MW, molecular weight. (C) HK20 binding to gp41 constructs by ELISA. (D–E) Neutralization of
96ZM651.2 (D) and CH064.20 (E) HIV-1 primary isolates by HK20 IgG and Fab fragments in a HOS-based assay.
doi:10.1371/journal.pone.0008805.g005
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gp41. Taken together, the above results indicate that HK20
recognizes a highly conserved site within the HR-1 region of gp41.
Since HR-1 occupies a restricted surface only transiently
exposed during the HIV-1 entry process, we hypothesized that
accessibility of the HK20 target epitope might be limited by the
size of an IgG molecule. We therefore compared intact IgG and
Fab fragments of HK20 for their capacity to neutralize a panel
of 22 pseudoviruses in the HOS-based assay. The HK20 Fab
fragments showed markedly increased breadth and potency
compared to IgG, being able to neutralize 21/22 isolates with
IC50 values ranging from 0.01 to 5.7 mg/ml (Figure 5D-E and
Table S4). By contrast, HK20 IgG neutralized 19/22 isolates
with IC50 values ranging from 1.46 to 84 mg/ml. In addition,
when the HK20 Fab fragment was tested in the TZM-bl assay it
neutralized 10 out of 33 isolates with IC50 values ranging between
0.4 and 8.8 mg/ml (Table S2), thus suggesting that the lack of
activity observed with HK20 IgG was possibly associated to a
different susceptibility of this cell line to this type of entry
inhibitors. Overall, these findings suggest that the reduced size of
the Fab molecule allows increased access to the HR-1 region and
imply that HR-1 accessibility is largely dependent on the target cell
used. This is similar in concept to the enhanced neutralization
profiles of Fab and ScFv specific for the CD4i surface [39]. Further
studies using M7 cells [52] challenged with replication-competent
HIV-1 viruses carrying a Luc reporter showed that HK20 exhibits
broad neutralization consistent with the results from the HOS cell
assay but unlike the TZM-bl assay, being able to neutralize 4 out 5
viruses tested (Table S5).
Broad Coverage of gp41 and gp120 Epitopes
The epitopes recognized by the 55 remaining mAbs were
mapped using three experimental approaches: i) cross-competition
against mAbs of known specificity or soluble CD4; ii) binding to
gp120 mutants or gp41 constructs representing different confor-
mational intermediates; iii) Pepscan analysis. The results of the
analysis performed on the gp120-specific and gp41-specific mAbs
are presented in Table 1 and Table 2, and the data are
summarized in a pie chart in Figure 6.
Thirty-seven mAbs bound to gp120 targeting primarily the
CD4bs and the V3 loop and to a lesser extent the CD4i site
(Table 1). A first group of mAbs was assigned to the V3 loop
based on cross-competition with two V3 loop specific mAbs
(HR10 and HGA9). This group comprised 8 mAbs, which were
already mapped to the V3 loop using the Pepscan analysis
approach, and 7 additional mAbs that were not analyzed by
peptide scanning (i.e. HGF9, HGT4, HGP21, HGP51, HGW48,
HGD129 and HGP27). Four mAbs (HX44, HGP105, HGW7,
HGY38) reacted with wt and CD4bs YU2 mutants but failed to
bind the CD4i mutant, and therefore were assigned to the CD4i
cluster. Notably, one mAb (HGP68) was mapped by Pepscan
analysis to a novel epitope in the V2 loop (TVYALFYRLDIVP)
and neutralized 4 Tier-1 isolates (Table S2). Fifteen other mAbs
were assigned tentatively or conclusively to the CD4bs based on
their capacity to inhibit gp120-sCD4 binding. Most of these mAbs
competed other CD4bs-specific mAbs, such as b12 and HJ16,
while in some cases this assay could not be performed due to lack
of epitope expression on the gp120 proteins used. Furthermore,
this group of mAbs showed variable reactivities with the YU2
mutants. While most of them did not bind the D368R mutant
similar to b12, others including HJ16, bound this mutant avidly. In
addition, most of these new CD4bs-specific mAbs also showed
decreased binding to the CD4i mutant, suggesting that they may
span a broader, as yet undescribed region that includes elements of
the CD4bs and CD4i sites. Finally, for 2 mAbs these analyses did
not provide any relevant information.
Twenty-one mAbs bound to gp41 by targeting primarily the
immunodominant C-C region, the HR-1 and the region
recognized by 5F3 mAb [64] (Table 2). MAbs HGK129,
HGN146 and HGN35 were assigned to the C-C loop since they
competed with 3D6 [43], reacted with an HR2 construct and
recognized synthetic peptides within this region. MAbs HGW17
and HGY25 were provisionally assigned to the C-C region since
they competed with 3D6. These data are consistent with the
immunodominance of the C-C region and with the notion that the
antibody response against this region overlaps with the 3D6
epitope. Several mAbs competed with 5F3 and HK20, and bound
both the HR-1 and 5HB constructs, suggesting that they may bind
between the fusion peptide and the HR-1 region. HGB33 was
provisionally assigned to the HR-1 region according to competi-
tion with HK20 and binding to the 5HB construct. Other mAbs
bound specifically the 5HB construct but did not compete with
any of the mAbs tested, thus indicating that the complete HR-1
coiled coil region exposed in 5HB harbors antibody epitopes
available for B cell recognition in the gp41 pre-hairpin
conformation [65,66]. The concomitant binding to recombinant
gp41 suggests that the latter may partially resemble the gp41 pre-
fusion state. Of note, three gp41 binding mAbs (HGP40, HGP48
and HGY50) neither competed with any of the mAbs tested, nor
bound to any constructs representing pre-hairpin conformations or
native gp140 (Figure S1), indicating that they recognize as yet
uncharacterized regions that are only available in the recombinant
gp41 protein. Interestingly, mAb HGF24 was assigned by Pepscan
analysis to an epitope in the C-terminal region of HR-2
(TNLIYTLIEESQN), proximal to the 2F5 epitope, and neutral-
ized 4 Tier-2 isolates (Table S2). This mAb competed with HK20
for gp41 binding, in spite of their distinct cognate specificities (HR-
2 and HR-1, respectively). This finding would be consistent with
the proximity of HR-1 and HR2 in the six-helix bundle structure.
Finally, although the gp41 protein used in the primary screening
includes the 2F5 and 4E10 epitopes, no MPER specific mAbs were
isolated, reinforcing the idea that this portion of gp41 is poorly
immunogenic in humans [21,22]
In conclusion, regardless of their limited breadth of neutraliza-
tion, this extended panel of human mAbs may represent a useful
tool for understanding the molecular basis of Env recognition in
humans.
Discussion
Using an improved EBV immortalization method combined
with a broad screening strategy we isolated from memory B cells of
HIV-1 infected donors 58 mAbs that cover an extensive antigenic
surface of Env. Of these, 37 neutralized at least one of the isolates
tested and 3 mAbs in particular bound to the CD4bs, V3 crown
and HR-1, showing considerable neutralizing breadth against a
panel of HIV-1 pseudoviruses of different clades and spanning
Tier-1 and Tier-2 isolates.
Severalstudieshavequestionedtheexistenceofindividualbroadly
neutralizing antibody specificities as part of a normal immune
response to HIV-1 infection. In this respect, b12 was isolated from a
phage library, while 2F5, 4E10 and 2G12, although isolated from
memory B cells, do not appear to have a counterpart in human sera
[22]. In a recent study, Nussenzweig and coworkers used trimeric
gp140 to isolate antigen-binding memory B cells from which
500 antibody sequences were retrieved by single-cell PCR [62].
Surprisingly, although the B cell donors had broadly neutralizing
serum activity, none of the mAbs isolated had this property. This
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from multiple clonal responses each of unique epitope specificity but
restrictedbreadthofviralstrainrecognition.However,analternative
interpretation might be that since available recombinant trimeric
antigens vary in structure, the ‘bait’ used for B cell isolation was not
optimal for enriching those secreting neutralizing antibodies. Our
results indicate that monoclonal antibodies with a limited spectrum
of neutralizing activity can be easily isolated, while those with a
broad pattern of cross-clade reactivity are rare, in line with the study
of Walker et al [40] and consistent with inferences from serum
neutralization specificity mapping analyses [21]. In this respect our
study demonstrates the feasibility of the EBV immortalization
method, which is limited only by the size of the blood samples
obtained (20–50 ml of peripheral blood).
Table 1. Epitope mapping of gp-120-specific mAbs.
Cross-competition with: Binding to: Neutralization
mAbs HR10 HGA9 HJ16 b12 2G12 sCD4 YU2 wt YU2 I420R YU2 D368R Specificity HOS TZM-bl
HGF9 ++ /222 222 2 2 V3 4/20 6/46
HGT4 ++ /222 222 2 2 V3 2/20 2/36
HGA13 ++ /222 22++ + V3 2/3 nd
HGA49 ++ /222 22++ + V3 5/20 8/46
HGA9 ++ 22 22++ + V3 7/20 11/46
HGD129 x + 22 22++ + V3 3/20 7/46
HGD65 x + xx x2 ++ + V3 6/20 7/46
HGI95 ++ 22 22++ + V3 9/20 8/46
HGN194 ++ 22 22++ + V3 11/20 19/92
HGP21 x + xx x2 ++ + V3 4/20 5/46
HGP51 x + xx x2 ++ + V3 4/20 5/46
HGW48 2 + 22 22++ + V3 6/20 nd
HR10 ++ 22 22++ + V3 8/20 9/46
HZ74 ++ 22 22++ + V3 6/20 12/46
HGP27 2 + 22 22++ /2 + V3 1/3 nd
HX44 22 2xx 2 + 2 + CD4i 3/20 2/46
HGP105 22 2xx 2 + 2 + CD4i 1/20 1/46
HGW7 22 2xx 2 + 2 + CD4i 1/20 nd
HGY38 22 2xx 2 + 2 + CD4i 2/3 nd
HGD14 x 2 x + 2 +/2 + 22CD4bs, 2/20 5/46
HR15 22 2x 2 +/22 2 2 CD4bs, 1/3 nd
HGF12 22 22 2+/2 ++ + CD4bs, 0/3 0/46
HGI46 x 2 xx 2 +/2 ++ /2 + CD4bs, 1/20 5/46
HGI75 22 +/2 x 2 +/2 ++ /22 CD4bs, 3/20 2/46
HGP172 22 +/2 + 2 +/2 ++ /22 CD4bs, 4/20 6/46
HGP134 22 +/2 x 2 ++ /22 2 CD4bs 6/20 4/46
HGI111 22 +/2 + 2 ++ + /22 CD4bs 7/20 4/46
HGP31 22 x +/22 ++ + /22 CD4bs 2/3 5/45
HGP61 22 +/2 x 2 ++ + /22 CD4bs 3/20 8/46
HGP82 22 ++ 2 ++ + /22 CD4bs 7/20 8/46
HGS2 22 2+ 2 ++ + /2 +/2 CD4bs 7/20 4/46
HGW26 22 2+ 2 ++ + /2 +/2 CD4bs 3/20 nd
HGZ1 22 +/2 + 2 ++ + /2 +/2 CD4bs 8/20 10/46
HJ16 x 2 + x 2 ++ /2 +/2 + CD4bs 10/20 33/92
HGP68 22 2x 22++ /2 + V2 6/20 4/46
HR12 22 2x 222 2 2 ? 0/20 2/46
HP12 x 22 x 222 2 2 ? 0/20 0/46
b12 22 +/2 + 2 ++ + 2 CD4bs 11/20 43/92
Cross competition with biotinylated mAbs of known specificity or sCD4: +, 90–100% inhibition, +/2, 50–90% inhibition, 2, ,50% inhibition. The x indicates that it was
not feasible to evaluate the competition due to the lack of binding to the immobilized gp120 protein. Binding by ELISA to YU2 gp120 wt and mutants in the CD4i and
the CD4bs. Specificity assignment (CD4bs, indicates partial inhibition of sCD4 binding). Shown is also the number of isolates neutralized in the HOS-based and TZM-bl
based assays.
doi:10.1371/journal.pone.0008805.t001
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this new panel of human mAbs reveal some interesting features of
thehumanantibodyresponsetoHIV-1withina populationofHIV-
1-infected donors. First, most of the gp120-specific mAbs showed
neutralizing activity (37 out of 58), indicating that they bind to sites
available on the functional Env trimer. The selection of a high-
percentage of trimer binding specificities may be a consequence our
use of trimeric Env antigens during the screening of the EVB-B cell
supernatants. The second aspect relates to gp41-specific antibodies,
which, with a few remarkable exceptions, were not neutralizing.
Interestingly the non-neutralizing antibodies bound gp41 in the
context of the recombinant trimer, whereas the most effective
neutralizing mAbs bound to gp41 fusion intermediates.
The three new neutralizing mAbs HJ16, HGN194 and HK20
show some interesting features. HJ16 showed a breadth of
neutralizing activity comparable to, and generally complementary
to b12, which aside from PG9 and PG16 [40] is currently the most
potent of the relatively broad neutralizing antibodies available.
HJ16 also showed selective neutralization of multiple Tier-2
isolates, making it particularly relevant as a template for vaccine
design. HGN194 binds to an extremely conserved epitope in the
V3 crown, and neutralizes all Tier-1, but only 11% of Tier-2
isolates tested. HGN194 showed broader activity than the well-
characterized V3-specific mAb 447-52D against a panel of 92
pseudoviruses. The preference for Tier-1 isolates characteristic of
V3-specific mAbs is consistent with the idea that the V3 loop is
displayed to varying degrees in the context of the native trimeric
Env protein of individual isolates [67,68] and with the recent
observation that sCD4 broadens neutralization of V3 mAbs [69].
The results obtained with HK20 are particularly intriguing, since
this mAb has a broad pattern of neutralization observed with HOS
but not TZMbl target cells. This mAb recognizes a highly
conserved epitope in the HR-1 trimer and it is more effective as an
Fab fragment as compared to intact IgG, a fact that is may be
explained by the limited accessibility of the epitope, which is likely
to be exposed only transiently on the cell surface during the viral
entry process [70]. Intriguingly, a recent study indicates that in
TZM-bl cells HIV-1 pseudoviruses penetrate the cytoplasm from
within endosomes rather than from the cell surface [71], a finding
that might help explain the lack of activity of HK20 in the TZMbl
assay if binding of this mAb is affected by the endosomal
environment. Further studies on primary cells will be required to
address the relative importance of these two entry pathways and to
establish whether HK20 may be capable of exerting a broad and
potent neutralizing activity in vivo. Preliminary studies using M7
cells [52] challenged with replication-competent HIV-1 viruses
Table 2. Epitope mapping of gp41-specific mAbs.
Cross-competition with: Binding to: Epitope Specificity Neutralization
mAbs 2F5 4E10 3D6 5F3 HK20 HR1 5HB HR2 HOS TZM-bl
HGN158 22 222 2 + 2 5HB 0/3 nd
HGN36 22 222 2 + 2 5HB 0/20 0/46
HGW34 22 22++ /2 + 2 5HB 0/3 nd
HGW46 22 222 2 + 2 5HB 0/20 0/46
HGK129 22 + 22 2 2 + LLGIWGCSGKLIC C-C 0/3 nd
HGN146 22 + 22 2 2 + LLGIWGCSGKLIC C-C 2/20 nd
HGN35 22 + 22 2 2 + SGKLIC C-C 0/3 nd
HGW17 22 + 2 2 222 C-C 0/20 nd
HGY25 22 + 2 2 222 C-C 0/20 nd
HGP40 22 222 2 2 2 gp41 only 0/20 0/46
HGP48 22 222 2 2 2 gp41 only 0/3 nd
HGY50 22 222 2 2 2 gp41 only 0/20 0/46
HK20 22 22++ + 2 QQHLLQLTVWGIKQL HR-1 17/20 3/92
HGB33 22 22+ 2 + 2 HR1/5HB 2/20 0/46
HGW63 22 2++ + + 2 HR1/5HB 0/20 nd
HGD161 22 2++ + + 2 HR-1/FP 0/20 0/46
HGP16 22 2+ + +++ /2 HR-1/FP 1/20 1/46
HGW23 22 2+/2 +/2 ++2 HR-1/FP 3/20 nd
HGN91 22 2+/2 +/2 ++2 HR-1/FP 0/3 nd
HGH8 22 2+/2 +/22+ 2 HR-1/FP 0/20 0/46
HGF24 22 22+/22++TNLIYTLIEESQN HR-2 2/20 4/46
3D6 22 + 22 2 2 +/2 GCSGKLICTTAVPW C-C nd nd
5F3 22 2+ 2 ++2 STMGAASITLTAQARQ FP nd nd
2F5 +/2 +/22 22 2 2 +/2 DKW MPER 10/20 35/90
4E10 ++ 222 2 2 +/2 WFDI MPER 20/20 89/90
Cross competition with biotinylated mAbs of known specificity: +, 90–100% inhibition, +/2, 50–90% inhibition, 2, ,50% inhibition. Binding to different gp41 constructs
by ELISA. Minimal linear epitopes using the Pepscan analysis and specificity assignment. C-C, C-C loop; 5HB, 5-helix bundle; FP, fusion peptideShown is also the number
of isolates neutralized in the HOS-based and TZM-bl based assays.
doi:10.1371/journal.pone.0008805.t002
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broad neutralization consistent with the results from the HOS cell
assay, and similar to Fab HK20 in the TZM-bl cell assay. Whereas
the TZM-bl assay is sensitive for certain antibodies such as CD4bs
mAbs, some mAbs such as 2G12 to other epitopes are less sensitive
to neutralization in this assay [72], perhaps owing to the
unnaturally high level of CCR5 expression on the TZM-bl cells
[60]. In this respect, low coreceptor expression levels have been
associated with delayed fusion kinetics and hence enhanced virus
sensitivity to HR-1 binding inhibitors, such as T-20 [73].
Therefore, despite the advantages of high throughput with the
TZM-bl assay, alternative neutralization assays might have closer
relevance to the in vivo situation.
In conclusion, we have shown that in HIV-1-infected
individuals a high proportion of HIV-specific B cells produce
neutralizing antibodies but only a few possess neutralizing activity
with relatively broad neutralization coverage. In the short term,
some of these reagents will be tested for their ability, singly or in
combination, to prevent HIV-1 or SIV transmission in a macaque
challenge model as done previously with other mAbs [5,6,7,8,9].
In the longer term, and combined with an atomic-level analysis of
epitope specificity, some of these mAbs may facilitate the template-
based design of immunogens for the development of a vaccine able
to induce neutralizing antibodies against the wide range of HIV-1
strains present in the global pandemic.
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